1062368-70-0

Basic information

• Product Name: Methyl 6-broMopyrazolo[1,...
• Synonyms: Methyl 6-broMopyrazolo[1,...;6-Bromopyrazolo[1,5-a]pyridine-3-carboxylic acid methyl ester;Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 6-broMo-, Methyl ester;Methyl 6-broMopyrazolo[1,5-a]pyridine-3-carboxylate;6-bromopyrazolo[1,5-a]pyridine-3-carboxylate
• CAS NO: 1062368-70-0
• Molecular Formula: C₉H₇BrN₂O₂
• Molecular Weight: 255.08
• Mol File: 1062368-70-0.mol

Chemical Properties

• Melting Point: 116-118℃
• Appearance: /
• Density: 1.68
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 6-broMopyrazolo[1,...(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-broMopyrazolo[1,...(1062368-70-0)
• EPA Substance Registry System: Methyl 6-broMopyrazolo[1,...(1062368-70-0)

Safety Data

• Hazardous Substances Data: 1062368-70-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate is used as a key intermediate in the synthesis of various drug molecules. Its unique structure allows it to be a versatile component in the development of new pharmaceuticals with diverse therapeutic applications.
Used in Organic Synthesis:
As a valuable building block, Methyl 6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate is used in the production of other pyrazole-containing compounds. These compounds have a wide range of applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Medicinal Chemistry Research:
Due to its potential biological activities, Methyl 6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate is under investigation for its therapeutic properties. Researchers are exploring its potential as a lead compound in the development of new drugs for various diseases and conditions.

Upstream product

• 55899-13-3 1-amino-3-bromopyridin-1-ium 2,4,6-trimethylbenzenesulfonate 
• 922-67-8 propynoic acid methyl ester 
• 626-55-1 3-Bromopyridine 

Downstream Products

• 1062368-36-8 methyl 6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyridine-3-carboxylate 
• 1264193-11-4 6- bromopyrazolo[1,5-a]pyridine 
• 2092835-01-1 6-bromopyrazolo[1,5-a]pyridine-3-carbonitrile 

Relevant articles and documents

In Situ Preparation and Consumption of O -Mesitylsulfonylhydroxylamine (MSH) in Continuous Flow for the Amination of Pyridines

The paper demonstrates a safe method in which highly unstable O -mesitylsulfonylhydroxylamine (MSH) can be prepared and consumed in continuous flow. MSH was prepared in situ and used for the flow amination of a range of pyridines, which were subsequently transformed into useful pyrazolopyridine building blocks.

METABOTROPIC GLUTAMATE RECEPTOR MODULATORS

The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders

INHIBITORS OF THE BMP SIGNALING PATHWAY

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.

Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors

A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline. The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examined by preparing and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivatives. In addition, increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t1/2 = 1.6 h) following intraperitoneal administration in mice. These studies provide useful molecular probes for examining the in vivo pharmacology of BMP signaling inhibition.